NIOX Group PLC
NIOX
Company Profile
Business description
NIOX Group PLC is a medical device company that develops a range of therapies for asthma, chronic obstructive pulmonary disease, and allergy. The company has a single operating segment: NIOX. The NIOX segment relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO). Geographically, it derives a majority of its revenue from the Asia Pacific and also has a presence in the European Union, the United States, the United Kingdom, and the Rest of the world.
Contact
1 Robert Robinson Avenue
The Magdalen Centre
The Oxford Science Park
OxfordOX4 4GA
GBRT: +44 3303309356
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
84
Stocks News & Analysis
stocks
Chart of the Week: Opportunities with wide-moat retailers
Consumer defensive names look undervalued.
stocks
New ASX share added to our best ideas
Earnings outlook is strong and the shares trade at a discount to our fair value.
stocks
Fair value downgraded for ASX heavyweight
Our capital allocation rating was also lowered due to balance sheet weakness.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,136.60 | 15.10 | 0.17% |
CAC 40 | 7,966.95 | 71.01 | 0.90% |
DAX 40 | 24,113.62 | 232.90 | 0.98% |
Dow JONES (US) | 46,441.10 | 43.21 | 0.09% |
FTSE 100 | 9,446.43 | 96.00 | 1.03% |
HKSE | 26,855.56 | 232.68 | 0.87% |
NASDAQ | 22,755.16 | 95.15 | 0.42% |
Nikkei 225 | 44,550.85 | 381.78 | -0.85% |
NZX 50 Index | 13,416.96 | 17.03 | -0.13% |
S&P 500 | 6,711.20 | 22.74 | 0.34% |
S&P/ASX 200 | 8,845.70 | 12.30 | 0.14% |
SSE Composite Index | 3,882.78 | 20.25 | 0.52% |